Emapalumab-lzsg and Rubella virus vaccine, live Subcutaneous
Determining the interaction of Emapalumab-lzsg and Rubella virus vaccine, live Subcutaneous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:If you are currently being treated with emapalumab, or have been treated within the last four weeks, you should talk to your doctor before receiving rubella virus vaccine. Because emapalumab affects the immune system, you may be at risk for developing an infection from the vaccine. In some situations, your doctor may want to delay vaccination to give your body time to recover from the effects of emapalumab therapy. If you have recently been vaccinated with rubella virus vaccine, your doctor may choose to postpone treatment with emapalumab. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: The administration of live or live attenuated vaccines during emapalumab therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Emapalumab is a monoclonal antibody that binds to and neutralizes interferon gamma, which may increase susceptibility to certain pathogens and increase the risk of fatal and serious infections. In clinical trials, serious infections such as sepsis, pneumonia, bacteremia, disseminated histoplasmosis, necrotizing fasciitis, viral infections, and perforated appendicitis were observed in 32% of patients receiving emapalumab. The reported infections were 41% viral, 35% bacterial, 9% fungal, while in 15% of cases the pathogen was not identified. The safety of immunization with live vaccines during or following emapalumab therapy has not been studied.
MANAGEMENT: The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.
- "Product Information. Gamifant (emapalumab)." Sobi Inc, Ardmore, PA.
Generic Name: emapalumab
Brand name: Gamifant
Synonyms: Emapalumab
Generic Name: rubella virus vaccine
Brand name:
Synonyms: Rubella virus vaccine, live (Subcutaneous)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Emapalumab-lzsg-Rubex
- Emapalumab-lzsg-Rubraca
- Emapalumab-lzsg-Rubramin PC
- Emapalumab-lzsg-Rucaparib
- Emapalumab-lzsg-Rucaparib Camsylate
- Emapalumab-lzsg-Ruconest
- Rubella virus vaccine, live Subcutaneous-Embeda
- Rubella virus vaccine, live Subcutaneous-Embeline
- Rubella virus vaccine, live Subcutaneous-Embeline (Clobetasol Cream, Gel, and Ointment)
- Rubella virus vaccine, live Subcutaneous-Embeline (Clobetasol Solution)
- Rubella virus vaccine, live Subcutaneous-Embeline E
- Rubella virus vaccine, live Subcutaneous-Embeline Scalp Application